panitumumab,bevacizumab
roche,takeda,amgen
['beva', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bevacizumab', 'crcsm', 'rectal', 'colorectal', 'panitumumab']
michael j. overman, md, and takayuki yoshino, phd, md, on colorectal cancer: phase iii data on panitumumab or bevacizumab plus mfolfox6 #crcsm #immunotherapy #oncology #cancer #asco22 
News and views from the world of clinical oncology and hematology